Actively Recruiting
Efficacy of 0.5% Topical Timolol Eye Drops in the Treatment of Post-Inflammatory Erythema Following Acne Vulgaris
Led by Pham Ngoc Thach University of Medicine · Updated on 2026-04-01
60
Participants Needed
1
Research Sites
30 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Post-inflammatory erythema (PIE) is a common sequela of acne vulgaris, characterized by persistent erythematous macules resulting from superficial vascular dilation. Current treatment options include energy-based devices such as intense pulsed light (IPL); however, these modalities may be costly and require specialized equipment. Timolol, a non-selective beta-adrenergic receptor blocker, has demonstrated vasoconstrictive properties and has been used off-label in dermatology for vascular-related conditions. This study aims to evaluate the efficacy and safety of topical 0.5% timolol ophthalmic solution in improving post-inflammatory erythema secondary to acne vulgaris and to compare its clinical outcomes with those achieved by intense pulsed light (IPL) therapy. This prospective comparative study will assess changes in erythema severity using standardized clinical evaluation and objective measurement tools over a defined treatment period. The findings may provide evidence for a cost-effective and accessible therapeutic alternative for managing post-acne erythema.
CONDITIONS
Official Title
Efficacy of 0.5% Topical Timolol Eye Drops in the Treatment of Post-Inflammatory Erythema Following Acne Vulgaris
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 12 years or older with a history of acne vulgaris
- Clinically diagnosed with post-inflammatory erythema secondary to acne vulgaris
- Willing and able to provide informed consent or assent with parental/guardian consent if under 18 years old
You will not qualify if you...
- Refusal or inability to comply with study procedures or follow-up
- Presence of post-inflammatory hyperpigmentation at the study site interfering with erythema assessment
- Other skin conditions affecting the treatment area (e.g., atopic dermatitis, rosacea, lupus erythematosus)
- Known allergy or adverse reaction to timolol or beta-adrenergic blockers
- Pregnant or breastfeeding women
- History of cardiovascular or respiratory conditions contraindicating beta-blocker use (asthma, atrioventricular block, bradycardia below 50 bpm, hypotension)
- Use of other topical medications or cosmetic products (except sunscreen) on the study area during the study period
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ho Chi Minh City Hospital of Dermato-Venereology
Ho Chi Minh City, Vietnam
Actively Recruiting
Research Team
P
Pham Duc Vu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here